REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

Overview

About this study

The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years.
  • Stage 3 acute kidney injury according to the KDIGO criteria.
  • Started or intending to start CKRT for volume management.
  • Attending intensivist or nephrologist intending to remove fluid using CKRT for at least 48 hours.

Exclusion Criteria:

  • Respiratory distress due to pulmonary edema or fluid overload.
  • Massive volume infusion (i.e., > 200 mL/h for > 6 hours of continuous infusion).
  • No intention to remove fluid as determined by attending intensivist or nephrologist.
  • Attending intensivist or nephrologist believes that the protocol will not be followed.
  • Continuous fluid removal for > 24 hours prior to study enrollment.
  • Actual or estimated premorbid body weight > 120 kilograms.
  • Patients treated with intermittent hemodialysis during the current admission.
  • Patients on chronic outpatient hemodialysis. 
  • Patients with history of, or current admission for kidney transplantation.
  • Do not resuscitate, intubate, or comfort measures only orders (i.e., DNR/DNI/CMO).
  • Moribund not expected to survive > 24 hours.
  • Confirmed pregnancy.
  • Patients treated with extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), or intra-aortic balloon pump (IABP).
  • Organ donors with neurological determination of death (i.e., brain dead donors).
  • Drug overdose requiring CKRT.
  • Enrollment in a concurrent interventional clinical trial with direct impact on fluid balance (e.g., > 500 mL study drug administration).

Eligibility last updated 3/9/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Kianoush Banaei Kashani, M.D., M.S.

Open for enrollment

Contact information:

Justin Patri CCRP

(507) 293-3732

Patri.Justin@mayo.edu

More information

Publications

Publications are currently not available